Solventum [SOLV] vs ResMed [RMD] Detailed Stock Comparison
Solventum
NYSE
Loading...
ResMed
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Solventum wins in 6 metrics, ResMed wins in 12 metrics, with 0 ties. ResMed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Solventum | ResMed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 34.45 | 30.29 | ResMed |
| Price-to-Book Ratio | 3.96 | 7.07 | Solventum |
| Debt-to-Equity Ratio | 242.58 | 14.27 | ResMed |
| PEG Ratio | 13.52 | 28.02 | Solventum |
| EV/EBITDA | 14.24 | 22.50 | Solventum |
| Profit Margin (TTM) | 4.56% | 27.22% | ResMed |
| Operating Margin (TTM) | 7.73% | 33.87% | ResMed |
| EBITDA Margin (TTM) | 7.73% | 33.87% | ResMed |
| Return on Equity | 10.66% | 25.86% | ResMed |
| Return on Assets (TTM) | 3.72% | 14.02% | ResMed |
| Free Cash Flow (TTM) | $805.00M | $1.65B | ResMed |
| Dividend Yield | N/A | 0.63% | N/A |
| 1-Year Return | 19.79% | 29.60% | ResMed |
| Price-to-Sales Ratio (TTM) | 1.56 | 8.20 | Solventum |
| Enterprise Value | $20.17B | $41.86B | ResMed |
| EV/Revenue Ratio | 2.43 | 8.13 | Solventum |
| Gross Profit Margin (TTM) | 53.82% | 60.84% | ResMed |
| Revenue per Share (TTM) | $48 | $35 | Solventum |
| Earnings per Share (Diluted) | $2.17 | $9.52 | ResMed |
| Beta (Stock Volatility) | N/A | 0.77 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Solventum vs ResMed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Solventum | 2.15% | 3.01% | 0.89% | 1.25% | -3.55% | 11.59% |
| ResMed | 1.87% | 3.10% | 9.85% | 19.65% | 27.90% | 28.56% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Solventum | 19.79% | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% |
| ResMed | 29.60% | 32.82% | 62.98% | 459.81% | 860.22% | 1,521.03% |
Performance & Financial Health Analysis: Solventum vs ResMed
| Metric | SOLV | RMD |
|---|---|---|
| Market Information | ||
| Market Cap | $12.93B | $42.22B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 526,194 | 918,860 |
| 90 Day Avg. Volume | 705,438 | 1,072,643 |
| Last Close | $73.55 | $293.73 |
| 52 Week Range | $59.35 - $85.92 | $199.92 - $293.81 |
| % from 52W High | -14.40% | -0.03% |
| All-Time High | $96.05 (Mar 25, 2024) | $301.34 (Sep 06, 2021) |
| % from All-Time High | -23.43% | -2.53% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.03% | 0.10% |
| Quarterly Earnings Growth | -0.42% | 0.30% |
| Financial Health | ||
| Profit Margin (TTM) | 0.05% | 0.27% |
| Operating Margin (TTM) | 0.08% | 0.34% |
| Return on Equity (TTM) | 0.11% | 0.26% |
| Debt to Equity (MRQ) | 242.58 | 14.27 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $18.86 | $40.77 |
| Cash per Share (MRQ) | $3.09 | $8.26 |
| Operating Cash Flow (TTM) | $772.00M | $1.75B |
| Levered Free Cash Flow (TTM) | $1.05B | $1.21B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.63% |
| Last 12-Month Dividend | N/A | $1.59 |
Valuation & Enterprise Metrics Analysis: Solventum vs ResMed
| Metric | SOLV | RMD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 34.45 | 30.29 |
| Forward P/E | 13.52 | 28.02 |
| PEG Ratio | 13.52 | 28.02 |
| Price to Sales (TTM) | 1.56 | 8.20 |
| Price to Book (MRQ) | 3.96 | 7.07 |
| Market Capitalization | ||
| Market Capitalization | $12.93B | $42.22B |
| Enterprise Value | $20.17B | $41.86B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.43 | 8.13 |
| Enterprise to EBITDA | 14.24 | 22.50 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.77 |
| Book Value per Share (MRQ) | $18.86 | $40.77 |
Financial Statements Comparison: Solventum vs ResMed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SOLV | RMD |
|---|---|---|
| Revenue/Sales | $2.07B | $1.35B |
| Cost of Goods Sold | $956.00M | $527.93M |
| Gross Profit | $1.11B | $820.07M |
| Research & Development | $193.00M | $86.44M |
| Operating Income (EBIT) | $152.00M | $456.57M |
| EBITDA | $271.00M | $532.89M |
| Pre-Tax Income | $38.00M | $458.05M |
| Income Tax | $-99.00M | $78.35M |
| Net Income (Profit) | $137.00M | $379.71M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SOLV | RMD |
|---|---|---|
| Cash & Equivalents | $534.00M | $1.21B |
| Total Current Assets | $3.05B | $3.51B |
| Total Current Liabilities | $2.57B | $1.02B |
| Long-Term Debt | $7.81B | $811.41M |
| Total Shareholders Equity | $3.26B | $5.97B |
| Retained Earnings | $378.00M | $6.08B |
| Property, Plant & Equipment | $0 | $288.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SOLV | RMD |
|---|---|---|
| Operating Cash Flow | $115.00M | $441.40M |
| Capital Expenditures | $-109.00M | $-30.59M |
| Free Cash Flow | $-80.00M | $504.99M |
| Debt Repayment | $-100.00M | $-5.00M |
| Common Stock Repurchase | N/A | $-100.01M |
Short Interest & Institutional Ownership Analysis
| Metric | SOLV | RMD |
|---|---|---|
| Shares Short | 3.85M | 9.02M |
| Short Ratio | 4.82 | 9.55 |
| Short % of Float | 0.03% | 0.07% |
| Average Daily Volume (10 Day) | 526,194 | 918,860 |
| Average Daily Volume (90 Day) | 705,438 | 1,072,643 |
| Shares Outstanding | 172.79M | 146.39M |
| Float Shares | 138.34M | 145.51M |
| % Held by Insiders | 0.20% | 0.01% |
| % Held by Institutions | 0.68% | 0.65% |
Dividend Analysis & Yield Comparison: Solventum vs ResMed
| Metric | SOLV | RMD |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.59 |
| Last 12-Month Dividend Yield | N/A | 0.63% |
| 3-Year Avg Annual Dividend | N/A | $1.60 |
| 3-Year Avg Dividend Yield | N/A | 0.23% |
| 3-Year Total Dividends | N/A | $4.79 |
| Ex-Dividend Date | N/A | Feb 13, 2025 |